SLC5A1 and Hyperglycemia: Dual SGLT1/2 inhibitors, sotagliflozin and licogliflozin, exert more selectivity for SGLT1 than canagliflozin, which may give dual SGLT1/2 inhibitors specific anti-hyperglycemia efficacy and cardiovascular and renal safety characteristics (161).